Latest news with #PIONEER
Irish Independent
16-07-2025
- Entertainment
- Irish Independent
Around the Districts: Kiltealy-Ballindaggin to Oylegate
FRIENDS OF ST LUKE'S CANCER CARE Two great nights of entertainment at Jordan's Pub, Ballindaggin on Saturday and Sunday, July 19 and 20. A weekend of music, bingo, live bands and great craic. The event is being hosted by Betty Codd in aid of the friends of St Luke's Cancer Care. Admission each night €10. Raffle and door prizes. It all kicks off Saturday, July 19, at 8.30 p.m. with music bingo, please contact 087 7152143 for tickets at €10 each. On Sunday, July 20, it all starts again from 5 p.m., with a selection of live bands performing, pay on the door. Please support this worthy cause, and spread the word. EUCHARISTIC ADORATION Eucharistic Adoration has ceased in Kiltealy Church for July and August, it will resume on Monday, September 1, Eucharistic Adoration continues in Ballindaggin Church every Thursday morning from 10 a.m. to 11 a.m. PIONEER PILGRIMAGE TO KNOCK The annual Pioneer pilgrimage to Knock Shrine takes place on Sunday next, July 20, Prayers will be offered at Our Lady's Shrine for all who work in alcohol and drug treatment centres around Ireland. Contact Fr Robert McCabe via prayer@ for further details. KILTEALY NS SPLIT THE POT The next draw split-the-pot will be Monday, July 28, all envelopes will roll over to that draw. Envelopes are available in local shops and pubs. Many thanks for your continued support of the school. WEDDING Congratulations to Michéal Doyle, Boolamore, Kiltealy and Evelyn Egan, Offaly, who were married in the Church of SS Patrick and Cecilia, Kiltealy on Friday last. The couple celebrated with family and friends afterwards at Riverside Park Hotel, Enniscorthy. We wish Michéal and Evelyn every happiness for the future. KILTEALY ANNUAL PATRON and FIELD DAY Following a meeting in Kiltealy Hall last week plans are now well under way for Kiltealy annual patron and field day on Sunday, August 3, Prayers in Churchyard Cemetery at 1 p.m. with Mass in New Cemetery at 1.30 p.m. Field day will follow immediately afterwards. Tickets for the annual draw will be distributed to all houses in the area in the coming weeks with fantastic prizes including first prize €250 cash; second dinner for four in Riverside park Hotel; third €100 voucher for Holy Grail; fourth €100 voucher for Mr Oil; fifth two planters from Kiltealy Wood Hub, plus five further prizes of brandy, whiskey and wine. Tickets €2 each or book of three €5. As always the field day will have many attractions with something for everyone to enjoy. ADULT EDUCATION Free full time adult education courses for anyone wanting to make a fresh start. If you are over 21 years and in receipt of a Social Welfare Payment and want to upskill, retain or find a new career path, at VTOS you can return to learning in a relaxed, friendly environment. Apply for QQ1 accredited L4 office skills course starting this autumn at VTOs Enniscorthy. For further information contact Aislinn Brennan at 053 9237224 or email enniscorthyvtos@ KILTEALY HALL BOOKINGS If any group would like to use Kiltealy Community Hall, it is essential to book the venue in advance. For bookings please call 086 3706638 or 053 9255197. DUFFRY SOCIAL CLUB Duffry Social Club meets every Wednesday in Kiltealy Community Hall from 2 p.m. to 5 p.m. for chat, bingo, cards and refreshments. New members are always welcome. Marshalstown-Castledockrell Monart Fundraiser Parishioners of St Peter's Church, Monart are organising a very unique fundraiser where you have the opportunity to win a signed Leister Rugby Jersey kindly donated by Charlie Tector. There are a limited number of tickets on sale priced at €10 each which can be purchased from any of the Monart parishioners or Rosemary in St Mary's Church. The draw will take place during the Parish Picnic in the grounds of St Peter's Church, Monart on Sunday, July 27. ADVERTISEMENT Learn more Omitted Items It has been brought to my attention that items relating to our community appear in notes from other areas but not in ours. The reason for this is I am sometimes asked not to put items in our local notes and I have to respect the wishes of the people involved. I hope this clears up the confusion as it was thought incorrectly by some that I omitted items. Notes Items should be received by 5 p.m. on Sunday evening at the latest for inclusion in the following week's paper. (Thursday at 5 p.m. prior to public holidays). Items received after these times will be held over to the next edition if it has not already happened. Priest on Duty The Emergency Number to contact Fr Tom, Fr James and Fr Billy is 087 2710478. Mass Times Marshalstown is on Tuesday at 9.30 a.m. and Saturday at 7.30 p.m. (Vigil Mass). Castledockrell is on Thursday at 9.30 a.m. and Sunday at 9.30 a.m. This is followed by Adoration of the Blessed Sacrament from 10 a.m. to 11 a.m. Changes in weekday Masses will be announced at weekend Masses where possible. Get Well Get well wishes to all in the parish who are ill at home, in hospitals or nursing homes at present and best wishes to all on the road to recovery. Lotto Marshalstown-Castledockrell GAA lotto results for July 10 are jackpot €14,000. No jackpot winner. Numbers drawn were 5, 16, 24 and 28. One match-three winner Larry Morrissey, who wins €100. Tickets are available from committee members, Redmond's Scarawalsh, The Hollow and online through clubforce app. Thanks for continued support. Happy Anniversary To all celebrating anniversaries at this time especially significant ones. Hope all enjoyed their celebrations. Oulart and the Ballagh First Anniversary The first anniversary Mass for the repose of the soul of Fr John Jordan, former parish priest of Oulart, was celebrated in Castledockrell Church, last Friday, July 11, with four priests concelebrating. Among the congregation were quite a few of his former parishioners from Oulart, there to pay their respects to a much-loved and respected pastor who ministered to them from 1997 till his retirement in Cards were available on the night and are also available at the back of St Patrick's Church, Oulart. Parish Committee At the meeting on July 1 the following officers were appointed – chairman Fr Doyle, Vice-Chair Martin Dempsey, secretary Kathryn O'Dowd, Assistant secretary Tara Finn, treasurer Josie Sinnott and Assistant treasurer Muriel O'Dowd It was agreed that problems with the heating system and the chutes at St Patrick's Church needed immediate attention and it was decided to run some bingo sessions at the GAA grounds to raise funds to defray the cost. Watch this space to learn the date and time of the bingo. The next meeting of the Parish Committee will be held on July 15. Oulart Active Retired Oulart Active Retired hold their regular weekly meeting on Tuesdays, 2 p.m. to 4 p.m., at which they play Indoor Bowls and enjoy a chat and a cuppa. Occasionally, they host other Active Retired groups. The yearly membership fee, covering insurance etc, is €15. Fit four Life 'Fit for Life' organised by Oulart Active Retired is held in Oulart Community Centre on Thursdays, 2 p.m. to 4 p.m. It consists of chair exercises, dance and movements to music along with fun games, especially suitable to the older person, but open to all. To cover costs, a fee of €5 per session, applies. Social dancing Every Monday night, social dancing is held in Oulart Community Centre. Doors open at 8 p.m., with dancing from 9 p.m. to 11 p.m. €10 admission. Refreshments served. Oylegate Patron Sunday 2025 Thank you to everyone who took the time to be present at our annual Patron; for the hard work and dedication you showed in caring for your loved ones' graves, ensuring that their memory lives on in a space of beauty and peace. Patron Sunday is more than a day of remembrance—it is a testament to the strength of our community and the love that binds us across generations. Thank you to everyone who made this day so meaningful, and for your generosity in our cemetery collection. The proceeds of the Patron Day Collection amounted to €2,490. A word of thanks to all who donated to this collection. Summer Painting & Drawing Classes Painting and Drawing classes will be held in Oylegate Community Centre, beginning the first week in July. Drawing sessions: Tuesdays 10.00am—12.00pm. (€15). Oil painting classes: Wednesdays 10.00am—12.00pm. (€20). All levels welcome. For more information contact Polly Maher at 087 3615980. Church news Weekly Devotions in Glenbrien - Everyone is welcome to join the following weekly occasions in our Parish: Every Monday at 6 p.m. in the Church: Divine Mercy Chaplet (Devotion to The Divine Mercy); Every Tuesday 10 a.m. to 6 p.m. in the Church: Eucharistic Adoration of The Blessed Sacrament; Every Friday & Sunday at 7 p.m. at the Grotto: The Holy Rosary Flower Rota for Church: Oylegate - If you would like to join the rota for the preparation of flowers for the altar during the year, please contact the parish office. Parish Office Hours - Monday, Wednesday and Friday 9am to 1pm. Mass Bookings - Please book anniversary Masses through the Parish Office during office hours. Charitable Donations Tax Back Campaign - This campaign was set up by the Revenue Commissioners to allow donations by parishioners to the parish by way of weekly envelope collections go even further. For every €250 that is contributed, the Revenue will refund €112 approximately to the parish. Forms are being sent out at present and you are asked to return your completed form at your convenience. If you have any query, please do not hesitate to contact the parish office on 086 8259842. Weekday Masses - Oylegate: Wednesday and Friday at 9.30am. Glenbrien: Tuesday and Thursday at 9.30am. Note: Should a funeral come to the church during the weekdays, any scheduled 9.30am Masses will be cancelled. Priest on Duty - Sunday night to Monday: Fr. Denis Kelly, ph 087 9470513. Tuesday to Saturday: Fr. Dermot Gahan, ph 087 2681010 / Fr Jim Finn 087 2119151. Church Weekly Envelopes - The weekly Envelope collection supports the running costs of the Churches in the Parish. If you do not take the box of envelopes, you might consider making an annual donation by cash, cheque or by Direct Debit. Bank Details: BIC: BOFIIE2D IBAN: IE44 BOFI 906566 24140788. Please notify the parish office if you are setting up a Direct Debit. Thank you. Gardens in Church Grounds – The Gardens are a place for people to visit for a quite prayer or reflection during day light hours. Please NO litter, NO smoking, NO alcohol, NO drug use and NO loitering after dark. Car parking in Oylegate Church Grounds – The parking area in the church grounds is primarily for use by those attending church services, visiting the cemetery or Prayer Gardens. An increasing number of vehicles are now using the area for all day parking. This will limit parking space for funerals. Perhaps, it is time to ask for donations from those who are availing of this facility. In general, proper regulations need to be put in place for all vehicles using the facility. Many are driving in the grounds at dangerous speeds. Some individuals are discarding litter from their vehicles which is doing nothing to enhance the overall appearance of the area. We should not have to continually clean-up other people's litter who are availing of the facility for free.
Business Standard
23-06-2025
- Business
- Business Standard
IndusInd Bank launches five new PIONEER branches strengthening its wealth management biz
IndusInd Bank has expanded its exclusive PIONEER branch network with the launch of five new branches across Delhi-NCR, Kochi, Surat and Goa, taking the total count to 15 PIONEER branches across key locations. This expansion is a strategic step towards scaling the Bank's affluent banking and wealth management franchise, offering high-net-worth individuals (HNIs) and ultra-HNIs a curated, high-touch banking experience supported by a seamless blend of personalized service and digital convenience. At the heart of the PIONEER proposition is the Client Ownership Model, where each client is served by a dedicated duo - a Relationship Manager and a Service Relationship Manager, trained to manage every aspect of the client's banking journey. This relationship-led approach is backed by over 900 certified RMs, 150+ SRMs (Service RMs), and 100+ domain specialists, ensuring both personalized attention and domain expertise. Clients also benefit from INDIE, the Bank's digital platform that enables one-touch access to their relationship team, real-time event-based updates, and seamless service requests such as doorstep banking, locker bookings, or card upgrades.
Yahoo
12-06-2025
- Business
- Yahoo
Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass., June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®/AYVAKYT® (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. "Our presentations feature large patient populations from the PIONEER, PATHFINDER and EXPLORER trials, with follow-up reaching up to five years in ISM and up to 6.5 years in advanced SM, reflecting both the favorable long-term benefits of AYVAKIT and the unprecedented datasets we have amassed over time," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "AYVAKIT has shown transformative clinical outcomes for patients across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM. These compelling results have translated into real-world practice, with clinicians expanding their view of who is an appropriate candidate for disease-modifying therapy after positive AYVAKIT experiences, and treatment durations trending toward multiple years." PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM As previously presented,1 AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3 percent) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. This data presentation follows the May 2025 online publication of PIONEER two-year efficacy and safety data in The Journal of Allergy and Clinical Immunology: In Practice. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells. Data Presentations EHA2025 Congress Oral Presentation: The Revised Mutation-Adjusted Risk Score (MARS-R) for Predicting Overall Survival in Patients with Advanced Systemic Mastocytosis Treated with Midostaurin or Avapritinib (Abstract S216) Poster Presentation: Blood-Based Proteomics for Deeper Insights Into Indolent Systemic Mastocytosis: The PIONEER Trial Experience (Abstract PS1838) Poster Presentation: High Accuracy of Peripheral Blood Testing Using Machine Learning–Derived Predictive Models to Distinguish Advanced from Indolent Systemic Mastocytosis: Analysis of Avapritinib and Elenestinib Trial Data (Abstract PF1310) Publication-Only Abstract: Phase 2/3 HARBOR Study of Elenestinib in ISM: A Trial-in-Progress Update of Novel Endpoints and Biomarkers Aimed at Evaluating Disease Modification (Abstract PB3108) EAACI Congress 2025 Flash Talk Presentation: Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study (Abstract 000621) Flash Talk Presentation: The Socio-Emotional Impact of Indolent Systemic Mastocytosis: Insights from the PRISM Survey (Abstract 000488) Poster Presentation: The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients with Indolent Systemic Mastocytosis (Abstract 001121) Data presentations are being made available in the "Science―Publications and Presentations" section of the company's website at About Systemic Mastocytosis Systemic mastocytosis (SM) is a rare disease driven by the KIT D816V mutation in about 95 percent of cases. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms across multiple organ systems. The vast majority of those affected have indolent systemic mastocytosis (ISM). A broad range of symptoms, including anaphylaxis, maculopapular rash, pruritus, diarrhea, brain fog, fatigue and bone pain, frequently persist in patients with ISM despite treatment with multiple symptom-directed therapies. This burden of disease can lead to a profound, negative impact on quality of life. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, and isolate themselves to protect against unpredictable triggers. Until 2023, there were no approved therapies for the treatment of ISM. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM (ASM), SM with an associated hematological neoplasm (SM-AHN) and mast cell leukemia (MCL). In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor survival. About AYVAKIT AYVAKIT (avapritinib) is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) to treat the root cause of SM. It was FDA approved for the treatment of advanced SM in June 2021 and ISM in May 2023. It now is indicated in adults with ISM, adults with advanced SM, including ASM, SM-AHN and MCL, and adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. The medicine is approved in the EU as AYVAKYT for the treatment of adults with ISM with moderate to severe symptoms inadequately controlled on symptomatic treatment, adults with ASM, SM-AHN or MCL, after at least one systemic therapy, and adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation. The therapy is not recommended for the treatment of patients with low platelet counts (less than 50,000/µL). Globally, the medicine is approved for one or more indications in 16 countries, including China where it is marketed by CStone Pharmaceuticals, paying tiered percentage royalties on sales. Please click here to see the full U.S. Prescribing Information for AYVAKIT, and click here to see the European Summary of Product Characteristics for AYVAKYT. Important Safety Information Intracranial Hemorrhage — Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In Advanced SM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study. Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs. In Advanced SM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in Advanced SM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction. Cognitive Effects — Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 Advanced SM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue. Photosensitivity — AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment. Embryo-Fetal Toxicity — AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose. Adverse Reactions — The most common adverse reactions (≥20%) in patients with Advanced SM were edema, diarrhea, nausea, and fatigue/asthenia. The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing. Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with Advanced SM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary. To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or AYVAKIT is available in 25-mg, 50-mg, 100-mg and 200-mg tablets. Please click here to see the full U.S. Prescribing Information for AYVAKIT. About Blueprint Medicines Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with SM in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases and solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Blueprint Medicines' leadership role and its ability to transform treatment across the spectrum of SM, including sustained disease control in ISM and prolonged survival in advanced SM; AYVAKIT/AYVAKYT's position as the durable standard of care and clinicians' view of appropriate candidates and treatment duration; plans and expectations for Blueprint Medicines' current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines' current or future approved drugs or drug candidates in treating patients; and Blueprint Medicines' strategy, goals, business plans and focus. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to Blueprint Medicines' ability and plans in continuing to build out and expand a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines' ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines' current or future drug candidates; Blueprint Medicines' advancement of multiple early-stage efforts; Blueprint Medicines' ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the preclinical and clinical results for Blueprint Medicines' drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and patient enrollment rates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines' ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT or any drug candidates it is developing; Blueprint Medicines' ability to successfully expand its operations, research platform and portfolio of therapeutic candidates, and the timing and costs thereof; the success of Blueprint Medicines' current and future collaborations, financing arrangements, partnerships or licensing arrangements; and the ability of the parties to consummate the proposed merger between Blueprint Medicines and Sanofi on the timeline anticipated or at all, including the occurrence of any event, change or other circumstance that could give rise to the termination of the merger. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Blueprint Medicines' filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines' most recent Annual Report on Form 10-K, as supplemented by any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements. Footnote 1 Reported at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) Joint Congress Trademarks Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation. View original content to download multimedia: SOURCE Blueprint Medicines Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
